Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. NMRA
NMRA logo

NMRA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Neumora Therapeutics Inc (NMRA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.780
1 Day change
52 Week Range
3.650
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

NMRA is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is weak in pre-market, lacks recent news catalysts, has bearish longer-term moving averages, and no strong proprietary buy signal is present. While options sentiment and hedge fund accumulation are constructive, the overall setup is not strong enough for an immediate long-term purchase at this time.

Technical Analysis

Current pre-market price is 1.73, down 2.81%. Short-term momentum is mixed to slightly improving because MACD histogram is positive and expanding, and RSI_6 at 58.31 is neutral. However, the trend structure remains bearish since SMA_200 > SMA_20 > SMA_5. Price is near the pivot at 1.75, with resistance at 1.899 and support at 1.601. The stock is not in a clear bullish trend yet, so the technical picture does not support an aggressive buy.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options activity is bullish overall because both the open interest put-call ratio and volume put-call ratio are low, showing call-side dominance. Call open interest is 56,080 versus put open interest of 13,471, and call volume also exceeds put volume. Implied volatility is extremely high at 303.33 with IV percentile 86.9, which suggests elevated option pricing and speculative trading interest. Despite bullish sentiment in options, this does not outweigh the weaker price action for a beginner long-term entry.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
3

Positive Catalysts

  • ["Hedge funds are buying, with buying amount up 327.95% over the last quarter.", "Options sentiment is bullish, with low put-call ratios and stronger call activity.", "MACD histogram is positive and expanding, suggesting short-term momentum improvement.", "Stock pattern analysis suggests a 4.13% expected move higher over the next month."]

Neutral/Negative Catalysts

  • ["Pre-market price is down 2.81%, showing immediate weakness.", "No news in the recent week, so there is no current event-driven catalyst.", "Moving averages are bearish, with SMA_200 above SMA_20 and SMA_5.", "No recent congress trading data is available.", "No significant insider buying trend; insiders are neutral.", "No recent AI Stock Picker or SwingMax signal."]

Financial Performance

No usable financial snapshot was provided because of an error, so latest quarter growth trends cannot be assessed. The latest quarter season is unavailable from the supplied data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no confirmed Wall Street consensus to summarize. Based on the available data, the pros are hedge fund buying and bullish options sentiment, while the cons are weak price action, bearish moving averages, no recent news, and no proprietary buy signal. Overall, Wall Street-style evidence in the provided dataset leans mixed to cautious rather than strongly bullish.

Wall Street analysts forecast NMRA stock price to rise
8 Analyst Rating
Wall Street analysts forecast NMRA stock price to rise
5 Buy
2 Hold
1 Sell
Moderate Buy
Current: 1.780
sliders
Low
3
Averages
9.33
High
18
Current: 1.780
sliders
Low
3
Averages
9.33
High
18
William Blair
Myles Minter
Market Perform
to
Outperform
upgrade
$7.62
AI Analysis
2026-02-17
Reason
William Blair
Myles Minter
Price Target
$7.62
AI Analysis
2026-02-17
upgrade
Market Perform
to
Outperform
Reason
William Blair analyst Myles Minter upgraded Neumora Therapeutics to Outperform from Market Perform with a net present value estimate of $7.62 per share. The firm increased its probability of success for NMRA-511 in Alzheimer's disease agitation to 35% after Neumora presented data from its Phase Ib study. The study showed meaningful reductions in the Cohen-Mansfield Agitation Inventory endpoint, the analyst tells investors in a research note. Blair continues to view Alzheimer's disease agitation as a blockbuster market opportunity with peak U.S. NMRA-511 sales of $1.8B "using conservative assumptions."
Mizuho
Outperform
maintain
$5 -> $6
2026-01-06
Reason
Mizuho
Price Target
$5 -> $6
2026-01-06
maintain
Outperform
Reason
Mizuho raised the firm's price target on Neumora Therapeutics to $6 from $5 and keeps an Outperform rating on the shares after the company made several announcements, highlighted by positive Phase 1b signal-seeking results for NMRA-511 in Alzheimer's disease agitation. Better results seen in a pre-specified subset of AD patients with elevated anxiety is "an encouraging finding," the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for NMRA
Unlock Now

People Also Watch